Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides.
The present study shows that a number of basic antifungal peptides, including human salivary histatin 5, a designed histatin analog designated dhvar4, and a peptide from frog skin, PGLa, are active against amphotericin B-resistant Candida albicans, Candida krusei, and Aspergillus fumigatus strains and against a fluconazole-resistant Candida glabrata isolate.
Helmerhorst
E J
EJ
Department of Oral Biochemistry, Vrije Universiteit, Amsterdam, The Netherlands. EJ.Helmerhorst.obc.acta@med.vu.nl
Reijnders
I M
IM
van't Hof
W
W
Simoons-Smit
I
I
Veerman
E C
EC
Amerongen
A V
AV
D000595:Amino Acid Sequence; D000666:Amphotericin B / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D001232:Aspergillus fumigatus / Q000187:drug effects / Q000302:isolation & purification; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D015725:Fluconazole / Q000494:pharmacology*; D005658:Fungi / Q000187:drug effects* / Q000302:isolation & purification; D054808:Histatins; D006801:Humans; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D010455:Peptides / Q000494:pharmacology*; D012471:Salivary Proteins and Peptides / Q000494:pharmacology
D000935:Antifungal Agents; C068075:HTN3 protein, human; D054808:Histatins; D010455:Peptides; D012471:Salivary Proteins and Peptides; D000666:Amphotericin B; D015725:Fluconazole